DekaBank Deutsche Girozentrale Has $22.54 Million Holdings in Royalty Pharma plc (NASDAQ:RPRX)

DekaBank Deutsche Girozentrale raised its position in Royalty Pharma plc (NASDAQ:RPRX) by 58.5% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 749,344 shares of the biopharmaceutical company’s stock after acquiring an additional 276,546 shares during the period. DekaBank Deutsche Girozentrale owned approximately 0.13% of Royalty Pharma worth $22,535,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Aurora Investment Counsel lifted its holdings in shares of Royalty Pharma by 7.0% in the first quarter. Aurora Investment Counsel now owns 43,385 shares of the biopharmaceutical company’s stock valued at $1,318,000 after purchasing an additional 2,827 shares in the last quarter. Atria Investments Inc bought a new position in shares of Royalty Pharma in the first quarter valued at approximately $1,185,000. Swedbank AB bought a new position in shares of Royalty Pharma in the first quarter valued at approximately $251,461,000. Advisory Resource Group bought a new position in shares of Royalty Pharma in the first quarter valued at approximately $824,000. Finally, Plato Investment Management Ltd bought a new position in shares of Royalty Pharma in the first quarter valued at approximately $1,163,000. Institutional investors and hedge funds own 54.35% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Morgan Stanley raised their target price on Royalty Pharma from $48.00 to $51.00 and gave the company an “overweight” rating in a report on Thursday, July 11th. UBS Group lowered Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price target on the stock. in a report on Monday, June 3rd. Bank of America dropped their price target on Royalty Pharma from $40.00 to $38.00 and set a “buy” rating on the stock in a report on Friday, April 12th. Finally, StockNews.com lowered Royalty Pharma from a “buy” rating to a “hold” rating in a report on Friday, May 10th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $41.80.

Royalty Pharma Stock Performance

Shares of RPRX traded up $0.04 during mid-day trading on Friday, hitting $28.53. The stock had a trading volume of 3,284,839 shares, compared to its average volume of 2,563,919. The firm has a market cap of $17.04 billion, a P/E ratio of 21.29, a PEG ratio of 3.74 and a beta of 0.46. The business has a fifty day moving average price of $27.12 and a 200-day moving average price of $28.40. The company has a debt-to-equity ratio of 0.62, a current ratio of 12.52 and a quick ratio of 12.52. Royalty Pharma plc has a 52 week low of $25.20 and a 52 week high of $31.66.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Thursday, May 9th. The biopharmaceutical company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.02. The firm had revenue of $568.00 million for the quarter, compared to analyst estimates of $671.45 million. Royalty Pharma had a return on equity of 22.94% and a net margin of 35.70%. During the same period in the previous year, the company posted $1.60 earnings per share. On average, equities research analysts expect that Royalty Pharma plc will post 4.01 EPS for the current year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 13th. Stockholders of record on Friday, August 16th will be given a $0.21 dividend. This represents a $0.84 annualized dividend and a dividend yield of 2.94%. The ex-dividend date of this dividend is Friday, August 16th. Royalty Pharma’s dividend payout ratio (DPR) is presently 62.69%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.